Reduced cortical renal GLUT1 expression induced by angiotensin-converting enzyme inhibition in diabetic spontaneously hypertensive rats

Brazilian Journal of Medical and Biological Research

Volumn 41, Issue 11, 2008, Pages 960-968

  Souza, M S ^a   Machado, U F ^b   Okamoto, M ^b   Bertoluci, M C ^c   Ponpermeyer, C ^a   Leguisamo, N ^a   Azambuja, F ^a   Irigoyen, M C ^a,b   Schaan, B D ^a,c  

^a INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Angiotensin converting enzyme inhibition; Diabetes mellitus; Diabetic nephropathy; Glucose transporter proteins; Hypertension; Streptozotocin

Indexed keywords

ALBUMIN; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 2; RAMIPRIL; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FLUOROMETRY; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HYPERTENSION; KIDNEY CORTEX; KIDNEY PARENCHYMA; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

RATTUS;

EID: 59849090700     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2008001100004     Document Type: Article

References (38)

1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
2. Christensen PK, Lund S, Parving HH. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. Kidney Int 2001; 60: 1435-1442.
3. Singh R, Alavi N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999; 48: 2066-2073.
4. Sharma K, Ziyadeh FN. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Semin Nephrol 1997; 17: 80-92.
5. Gruden G, Zonca S, Hayward A, Thomas S, Maestrini S, Gnudi L, et al. Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes 2000; 49: 655-661.
6. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994; 93: 536-542.
7. D'Agord SB, Lacchini S, Bertoluci MC, Irigoyen MC, Machado UF, Schmid H. Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Horm Metab Res 2001; 33: 664-669.
8. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol 1996; 270: G541-G553.
9. Schaan BD, Irigoyen MC, Lacchini S, Moreira ED, Schmid H, Machado UF. Sympathetic modulation of the renal glucose transporter GLUT2 in diabetic rats. Auton Neurosci 2005; 117: 54-61.
10. Marks J, Carvou NJ, Debnam ES, Srai SK, Unwin RJ. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 2003; 553: 137-145.
11. Dominguez JH, Camp K, Maianu L, Feister H, Garvey WT. Molecular adaptations of GLUT1 and GLUT2 in renal proximal tubules of diabetic rats. Am J Physiol 1994; 266: F283-F290.
12. Dominguez JH, Camp K, Maianu L, Garvey WT. Glucose transporters of rat proximal tubule: differential expression and subcellular distribution. Am J Physiol 1992; 262: F807-F812.
13. Chin E, Zamah AM, Landau D, Gronbcek H, Flyvbjerg A, LeRoith D, et al. Changes in facilitative glucose transporter messenger ribonucleic acid levels in the diabetic rat kidney. Endocrinology 1997; 138: 1267-1275.
14. Vestri S, Okamoto MM, de Freitas HS, Aparecida Dos Santos R, Nunes MT, Morimatsu M, et al. Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 2001; 182: 105-112.
15. Goestemeyer AK, Marks J, Srai SK, Debnam ES, Unwin RJ. GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-betal and plasma glucose concentration. Diabetologia 2007; 50: 2209-2217.
16. Li Y, Liu Z, Liu D, Zhang J, Chen Z, Li L. Identification and function of glucose transporter 1 in human mesangial cells. Chin Med J 2001; 114: 824-828.
17. Schaan BD, Irigoyen MC, Bertoluci MC, Lima NG, Passaglia J, Hermes E, et al. Increased urinary TGF-beta1 and cortical renal GLUT1 and GLUT2 levels: additive effects of hypertension and diabetes. Nephron Physiol 2005; 100: 43-50.
18. Obata J, Nakamura T, Takano H, Naito A, Kimura H, Yoshida Y, et al. Increased gene expression of components of the renin-angiotensin system in glomeruli of genetically hypertensive rats. J Hypertens 2000; 18: 1247-1255.
19. Quinn LA, McCumbee WD. Regulation of glucose transport by angiotensin II and glucose in cultured vascular smooth muscle cells. J Cell Physiol 1998; 177: 94-102.
20. Nose A, Mori Y, Uchiyama-Tanaka Y, Kishimoto N, Maruyama K, Matsubara H, et al. Regulation of glucose transporter (GLUT1) gene expression by angiotensin II in mesangial cells: involvement of HB-EGF and EGF receptor transactivation. Hypertens Res 2003; 26: 67-73.
21. Freitas HS, Schaan BD, Seraphim PM, Nunes MT, Machado UF. Acute and short-term insulin-induced molecular adaptations of GLUT2 gene expression in the renal cortex of diabetic rats. Mol Cell Endocrinol 2005; 237: 49-57.
22. Freitas HS, D'Agord SB, da Silva RS, Okamoto MM, Oliveira-Souza M, Machado UF. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats. Nephron Physiol 2007; 105: 42-51.
23. Linz W, Jessen T, Becker RH, Scholkens BA, Wiemer G. Long-term ACE inhibition doubles lifespan of hypertensive rats. Circulation 1997; 96: 3164-3172.
24. Santos RA, Krieger EM, Greene LJ. An improved fluorometric assay of rat serum and plasma converting enzyme. Hypertension 1985; 7: 244-252.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
26. Balbinott AW, Irigoyen MC, Brasileiro-Santos MS, Zottis B, de Lima NG, Passaglia J, et al. Dose-dependent autonomic dysfunction in chronic L-NAME-hypertensive diabetic rats. J Cardiovasc Pharmacol 2005; 46: 563-569.
27. Maeda CY, Schaan BD, Oliveira EM, Oliveira VL, De Angelis K, Irigoyen MC. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats. Clin Exp Pharmacol Physiol 2007; 34: 574-580.
28. Sharifi AM, Akbarloo N, Darabi R, Larijani B. Study of correlation between elevation of blood pressure and tissue ACE activity during development of hypertension in 1K1C rats. Vascul Pharmacol 2004; 41: 15-20.
29. Maeda S, Kikkawa R, Haneda M, Togawa M, Koya D, Horide N, et al. Reduced activity of renal angiotensin-converting enzyme in streptozotocin-induced diabetic rats. J Diabet Complications 1991; 5: 225-229.
30. Handa H, Sakurama S, Nakagawa S, Yasukouchi T, Sakamoto W, Izumi H. Glandular kallikrein, renin and angiotensin converting enzyme of diabetic and hypertensive rats. Adv Exp Med Biol 1989; 247B: 443-448.
31. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004; 43: 1120-1125.
32. Yan L, Yang R, Cheng H, Fu Z, Zhong G, Yan T. Protective effect of the angiotensin-converting enzyme inhibitor perindopril on diabetic glomerulopathy in streptozotocin-induced diabetic rats. Chin Med J 1998; 111: 306-308.
33. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995; 96: 1802-1814.
34. Tschope C, Seidl U, Reinecke A, Riester U, Graf K, Schultheiss HP, et al. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy. Int Immunopharmacol 2003; 3: 335-344.
35. Yasunaga S, Yonemochi H, Saikawa T, Sakata T. Bradykinin regulates captopril-induced upregulation of beta-adrenergic receptor in cultured neonatal rat cardiomyocytes. J Mol Cell Cardiol 2000; 32: 153-159.
36. Lindberg BF, Gyllstedt E, Andersson KE. Conversion of angiotensin I to angiotensin II by chymase activity in human pulmonary membranes. Peptides 1997; 18: 847-853.
37. Bertoluci MC, Uebel D, Schmidt A, Thomazelli FC, Oliveira FR, Schmid H. Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. Diabetes Res Clin Pract 2006; 72: 258-264.
38. Lehfeld LS, Silveira LA, Ghini B, Lopes de Faria JB. Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy. Kidney Blood Press Res 2004; 27: 114-120.